文献速递产科母胎医学

口服降糖药与胰岛素治疗妊娠期糖尿病的成本效果分析:SUGAR-DIP随机对照试验

Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost-Effectiveness Analysis of the SUGAR-DIP Randomized Controlled Trial.
PubMed 文献 · BJOG · 2026-10-25

该研究基于SUGAR-DIP随机对照试验,从社会医疗视角评估序贯口服降糖药(二甲双胍和格列本脲)与胰岛素治疗妊娠期糖尿病的成本效果。结果显示OHA略微增加QALYs(0.009;95%CI 0.004-0.014),但避免LGA无统计学差异,社会成本无显著差异,OHA在QALY方面具有高成本效果概率。

要点

  • OHA较胰岛素略微增加QALYs(0.009;95%CI 0.004-0.014),约相当于完美健康状态3天。
  • 避免LGA方面无统计学显著差异(-0.039;95%CI -0.097-0.018)。
  • 社会成本无显著差异(均值差-€1004;95%CI -€3503-€1495),OHA在QALY方面更具成本效果。

核心结论

  • 对于QALYs,OHA相比胰岛素具有高成本效果概率,但QALY增益较小且临床相关性有限。
  • 对于LGA,OHA成本更低但效果更差,成本效果取决于成本与新生儿结局之间可接受的权衡。

研究设计与样本

  • 基于SUGAR-DIP随机对照试验的成本效果分析,从社会医疗视角进行。

主要发现

  • OHA组QALYs增加0.009(95%CI 0.004-0.014),约相当于完美健康状态3天。
  • 避免LGA的差异为-0.039(95%CI -0.097-0.018),无统计学显著性。
  • 社会成本均值差为-€1004(95%CI -€3503-€1495),无统计学显著性。
  • 在WTP阈值为€0时,OHA对两种结局具有成本效果的概率均为79%。

关键数值与推荐

  • OHA在QALY方面较胰岛素更具成本效果(概率79% at WTP €0)。
  • LGA方面OHA成本更低但效果更差,成本效果需权衡成本与新生儿结局。

临床怎么用

  • OHA可作为GDM治疗中具有成本效果优势的选择,但需注意QALY增益的临床意义有限。
  • 对于以LGA为主要结局的决策,需结合可接受的新生儿结局权衡来评估OHA的成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the cost-effectiveness of treatment with sequential oral antihyperglycemic agents (OHA; metformin and glibenclamide) versus insulin for gestational diabetes (GDM). DESIGN: Cost-effectiveness analysis from a societal and healthcare perspective alongside a randomized controlled trial (SUGAR-DIP). SETTING: Twenty-five hospitals in the Netherlands. POPULATION: Women with GDM and a singleton pregnancy, randomized to OHA (n = 409) or insulin (n = 411) between 16 to 34 weeks' gestation. METHODS: Missing data were handled using multiple imputation. Differences in costs and effects were estimated using bivariate regression with bootstrapping to derive incremental cost-effectiveness ratios. Cost-effectiveness acceptability curves were constructed across a range of willingness-to-pay (WTP) thresholds. MAIN OUTCOME MEASURES: Large for gestational age (LGA), quality-adjusted life-years (QALYs), costs and cost-effectiveness. RESULTS: OHA slightly increased QALYs (0.009; 95% CI 0.004 to 0.014), corresponding to approximately 3 days in perfect health. There were no statistically significant differences in LGA avoided (-0.039; 95% CI-0.097 to 0.018) or societal costs (mean difference-€1004; 95% CI-€3503 to €1495). OHA were less costly and less effective than insulin for LGA, whereas for QALYs they were less costly and more effective. The probability of OHA being cost-effective at a WTP threshold of €0 was 79% for both outcomes. CONCLUSIONS: OHA have a high probability of being cost-effective compared with insulin for QALYs, although the QALY gain is small and of limited clinical relevance. For LGA, OHA were less costly but less effective, and cost-effectiveness depends on acceptable trade-offs between costs and neonatal outcomes.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Broulikova HM, van der Wel AWT, Rademaker D, et al. Oral Antihyperglycemic Agents Versus Insulin for Gestational Diabetes Mellitus: Societal Cost-Effectiveness Analysis of the SUGAR-DIP Randomized Controlled Trial. BJOG. 2026. PMID: 42928492. doi:10.1111/1471-0528.70347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。